Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery

Oncology Letters

Volumn 10, Issue 2, 2015, Pages 1079-1086

  Kolacinska, Agnieszka ^a,b   Cebula Obrzut, Barbara ^a   Pakula, Lukasz ^c   Chalubinska Fendler, Justyna ^a   Morawiec Sztandera, Alina ^a   Pawlowska, Zofia ^a   Zawlik, Izabela ^d,e   Morawiec, Zbigniew ^b   Jesionek Kupnicka, Dorota ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Cancer Center   (Poland)

^c Regional Oncol Center   (Poland)

^d UNIVERSITY OF RZESZÓW   (Poland)

^e Center for Innovative Research in Medical and Natural Sciences   (Poland)

Author keywords

Breast cancer; Cytotoxic T lymphocyte antigen 4; Programmed cell death protein 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; BIOPSY; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR VOLUME; VERY ELDERLY;

EID: 84931424481     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3321     Document Type: Article

References (40)

1. Urban JA and Baker HW: Radical mastectomy in continuity with en bloc resection of the internal mammary lymph-node chain; a new procedure for primary operable cancer of the breast. Cancer 5: 992-1008, 1952.
2. Halsted WS: I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 20: 497-555, 1894.
3. Giuliano AE, Kirgan DM, Guenther JM and Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220: 391-398, 1994.
4. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM and Morrow M: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305: 569-575, 2011.
5. Galimberti V, Cole BF, Zurrida S, et al; International Breast Cancer Study Group Trial 23-01 investigators: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14: 297-305, 2013.
6. Gentilini O and Veronesi U: Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast 21: 678-681, 2012.
7. Reimer T, Hartmann S, Stachs A and Gerber B: Local treatment of the axilla in early breast cancer: Concepts from the national surgical adjuvant breast and bowel project B-04 to the planned intergroup sentinel mamma trial. Breast Care Basel 9: 87-95, 2014.
8. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.
9. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
10. Ott PA, Hodi FS and Robert C: CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19: 5300-5309, 2013.
11. Eggermont AM, Spatz A and Robert C: Cutaneous melanoma. Lancet 383: 816-827, 2014.
12. Lipson EJ, Sharfman WH, Drake CG, et al: Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19: 462-468, 2013.
13. Loi S: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Presented at the San Antonio Breast Cancer Symposium, 2013. https://www.conferencenotes.co/conferences/5467ecb588d6868d254609f6/presentations/54739f542e0507a22d1b9341?referrer=history.
14. Beavis PA, Milenkovski N, Henderson MA, et al: Adenosine receptor 2A blockade increases the efficacy of anti-PD1 through enhanced antitumor T-cell responses. Cancer Immunol Res: Feb 11, 2015 (Epub ahead of print).
15. Denkert C, von Minckwitz G, Brase JC, et al: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33: 983-991, 2015.
16. Verbrugge I, Hagekyriakou J, Sharp LL, et al: Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 72: 3163-3174, 2012.
17. Bos PD, Plitas G, Rudra D, Lee SY and Rudensky AY: Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 210: 2435-2466, 2013.
18. Vonderheide RH, LoRusso PM, Khalil M, et al: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 16: 3485-3494, 2010.
19. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
20. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
21. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al; American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013, 2013.
22. Legat A, Speiser DE, Pircher H, Zehn D and Fuertes Marraco SA: Inhibitory receptor expression depends more dominantly on differentiation and activation than “exhaustion” of human CD8 T cells. Front Immunol 4: 455, 2013.
23. Poschke I, De Boniface J, Mao Y and Kiessling R: Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. Int J Cancer 131: 1611-1620, 2012.
24. Azim HA, Brohée S, Peccatori FA, et al: Biology of breast cancer during pregnancy using genomic profiling. Endocr Relat Cancer 21: 545-554, 2014.
25. Poland GA, Ovsyannikova IG, Kennedy RB, Lambert ND and Kirkland JL: A systems biology approach to the effect of aging, immunosenescence and vaccine response. Curr Opin Immunol 29: 62-68, 2014.
26. Martinet KZ, Bloquet S and Bourgeois C: Ageing combines CD4 T cell lymphopenia in secondary lymphoid organs and T cell accumulation in gut associated lymphoid tissue. Immun Ageing 11: 8, 2014.
27. Stagg J, Andre F and Loi S: Immunomodulation via chemotherapy and targeted therapy: A new paradigm in breast cancer therapy? Breast Care Basel 7: 267-272, 2012.
28. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175, 2010.
29. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133, 2013.
30. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014.
31. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Version 2. 2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast. Accessed March 11, 2015.
32. Vallacchi V, Vergani E, Camisaschi C, et al: Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res 74: 130-140, 2014.
33. Goldhirsch A, Winer EP, Coates AS, et al; Panel members: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24: 2206-2223, 2013.
34. Prat A, Cheang MC, Martín M, et al: Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31: 203-209, 2013.
35. Carroll JS: Steroids, nuclear receptors and breast cancer. Preface. Mol Cell Endocrinol 382: 623, 2014.
36. Denkert C: The immunogenicity of breast cancer -molecular subtypes matter. Ann Oncol 25: 1453-1455, 2014.
37. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25: 1544-1550, 2014.
38. von Minckwitz G, Schneeweiss A, Loibl S, et al: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 15: 747-756, 2014.
39. Denkert C: Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer. J Clin Oncol 31: 836-837, 2013.
40. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31: 860-867, 2013.